KAMADA LTD (KMDA) Stock Fundamental Analysis
NASDAQ:KMDA - Nasdaq - IL0010941198 - Common Stock - Currency: USD
Overall KMDA gets a fundamental rating of 6 out of 10. We evaluated KMDA against 557 industry peers in the Biotechnology industry. While KMDA belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. KMDA has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
KMDA had positive earnings in the past year.
In the past year KMDA had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: KMDA reported negative net income in multiple years.
KMDA had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 4.28%, KMDA belongs to the top of the industry, outperforming 91.92% of the companies in the same industry.
With an excellent Return On Equity value of 6.37%, KMDA belongs to the best of the industry, outperforming 93.18% of the companies in the same industry.
The Return On Invested Capital of KMDA (5.91%) is better than 93.36% of its industry peers.
The Average Return On Invested Capital over the past 3 years for KMDA is significantly below the industry average of 14.78%.
The last Return On Invested Capital (5.91%) for KMDA is above the 3 year average (2.98%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.28% | ||
| ROE | 6.37% | ||
| ROIC | 5.91% |
ROA(3y)1.84%
ROA(5y)2.59%
ROE(3y)2.55%
ROE(5y)3.2%
ROIC(3y)2.98%
ROIC(5y)N/A
1.3 Margins
KMDA has a better Profit Margin (9.60%) than 92.64% of its industry peers.
In the last couple of years the Profit Margin of KMDA has declined.
KMDA has a Operating Margin of 14.24%. This is amongst the best in the industry. KMDA outperforms 94.61% of its industry peers.
KMDA's Operating Margin has declined in the last couple of years.
KMDA's Gross Margin of 44.23% is fine compared to the rest of the industry. KMDA outperforms 75.40% of its industry peers.
In the last couple of years the Gross Margin of KMDA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.24% | ||
| PM (TTM) | 9.6% | ||
| GM | 44.23% |
OM growth 3YN/A
OM growth 5Y-7.02%
PM growth 3YN/A
PM growth 5Y-12.51%
GM growth 3Y14.12%
GM growth 5Y2.16%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), KMDA is destroying value.
The number of shares outstanding for KMDA remains at a similar level compared to 1 year ago.
KMDA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, KMDA has a worse debt to assets ratio.
2.2 Solvency
KMDA has an Altman-Z score of 3.11. This indicates that KMDA is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.11, KMDA is doing good in the industry, outperforming 72.89% of the companies in the same industry.
KMDA has a debt to FCF ratio of 0.30. This is a very positive value and a sign of high solvency as it would only need 0.30 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.30, KMDA belongs to the top of the industry, outperforming 95.69% of the companies in the same industry.
A Debt/Equity ratio of 0.04 indicates that KMDA is not too dependend on debt financing.
KMDA's Debt to Equity ratio of 0.04 is on the low side compared to the rest of the industry. KMDA is outperformed by 60.68% of its industry peers.
Even though the debt/equity ratio score it not favorable for KMDA, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | 0.3 | ||
| Altman-Z | 3.11 |
ROIC/WACC0.66
WACC8.97%
2.3 Liquidity
KMDA has a Current Ratio of 3.30. This indicates that KMDA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.30, KMDA is doing worse than 61.58% of the companies in the same industry.
KMDA has a Quick Ratio of 1.93. This is a normal value and indicates that KMDA is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of KMDA (1.93) is worse than 75.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.3 | ||
| Quick Ratio | 1.93 |
3. Growth
3.1 Past
KMDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.09%, which is quite impressive.
KMDA shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.60% yearly.
Looking at the last year, KMDA shows a quite strong growth in Revenue. The Revenue has grown by 11.83% in the last year.
Measured over the past years, KMDA shows a small growth in Revenue. The Revenue has been growing by 4.82% on average per year.
EPS 1Y (TTM)26.09%
EPS 3YN/A
EPS 5Y-13.6%
EPS Q2Q%75%
Revenue 1Y (TTM)11.83%
Revenue growth 3Y15.82%
Revenue growth 5Y4.82%
Sales Q2Q%16.65%
3.2 Future
KMDA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.03% yearly.
The Revenue is expected to grow by 9.00% on average over the next years. This is quite good.
EPS Next Y16.71%
EPS Next 2Y24.22%
EPS Next 3Y28.03%
EPS Next 5YN/A
Revenue Next Year12.1%
Revenue Next 2Y10.7%
Revenue Next 3Y9%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 26.55, which means the current valuation is very expensive for KMDA.
KMDA's Price/Earnings ratio is rather cheap when compared to the industry. KMDA is cheaper than 94.43% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.30. KMDA is around the same levels.
KMDA is valuated rather expensively with a Price/Forward Earnings ratio of 19.19.
Compared to the rest of the industry, the Price/Forward Earnings ratio of KMDA indicates a rather cheap valuation: KMDA is cheaper than 93.18% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.76. KMDA is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.55 | ||
| Fwd PE | 19.19 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of KMDA indicates a rather cheap valuation: KMDA is cheaper than 97.13% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, KMDA is valued cheaper than 96.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.12 | ||
| EV/EBITDA | 9.94 |
4.3 Compensation for Growth
KMDA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of KMDA may justify a higher PE ratio.
KMDA's earnings are expected to grow with 28.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.59
PEG (5Y)N/A
EPS Next 2Y24.22%
EPS Next 3Y28.03%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 2.54%, KMDA has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 80.15, KMDA pays a better dividend. On top of this KMDA pays more dividend than 98.56% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.37, KMDA has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.54% |
5.2 History
KMDA is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y24.22%
EPS Next 3Y28.03%
7.7
-0.01 (-0.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners10.27%
Inst Owner Change0%
Ins Owners2.34%
Ins Owner ChangeN/A
Market Cap442.83M
Analysts84.44
Price Target15.05 (95.45%)
Short Float %0.42%
Short Ratio1.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.54% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.18%
Min EPS beat(2)1.67%
Max EPS beat(2)28.68%
EPS beat(4)4
Avg EPS beat(4)17.92%
Min EPS beat(4)1.67%
Max EPS beat(4)38.4%
EPS beat(8)7
Avg EPS beat(8)38.21%
EPS beat(12)9
Avg EPS beat(12)-12.84%
EPS beat(16)9
Avg EPS beat(16)-100.15%
Revenue beat(2)1
Avg Revenue beat(2)-0.44%
Min Revenue beat(2)-3.06%
Max Revenue beat(2)2.19%
Revenue beat(4)2
Avg Revenue beat(4)1%
Min Revenue beat(4)-3.06%
Max Revenue beat(4)4.89%
Revenue beat(8)3
Avg Revenue beat(8)0.32%
Revenue beat(12)4
Avg Revenue beat(12)-0.47%
Revenue beat(16)5
Avg Revenue beat(16)-0.1%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)16.13%
EPS NQ rev (3m)22.73%
EPS NY rev (1m)0%
EPS NY rev (3m)2.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.55 | ||
| Fwd PE | 19.19 | ||
| P/S | 2.65 | ||
| P/FCF | 12.12 | ||
| P/OCF | 9.61 | ||
| P/B | 1.76 | ||
| P/tB | 2 | ||
| EV/EBITDA | 9.94 |
EPS(TTM)0.29
EY3.77%
EPS(NY)0.4
Fwd EY5.21%
FCF(TTM)0.64
FCFY8.25%
OCF(TTM)0.8
OCFY10.4%
SpS2.91
BVpS4.38
TBVpS3.85
PEG (NY)1.59
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.28% | ||
| ROE | 6.37% | ||
| ROCE | 7.49% | ||
| ROIC | 5.91% | ||
| ROICexc | 7.78% | ||
| ROICexgc | 8.89% | ||
| OM | 14.24% | ||
| PM (TTM) | 9.6% | ||
| GM | 44.23% | ||
| FCFM | 21.85% |
ROA(3y)1.84%
ROA(5y)2.59%
ROE(3y)2.55%
ROE(5y)3.2%
ROIC(3y)2.98%
ROIC(5y)N/A
ROICexc(3y)3.78%
ROICexc(5y)N/A
ROICexgc(3y)8.93%
ROICexgc(5y)N/A
ROCE(3y)3.78%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-12.12%
ROICexc growth 3YN/A
ROICexc growth 5Y-24.72%
OM growth 3YN/A
OM growth 5Y-7.02%
PM growth 3YN/A
PM growth 5Y-12.51%
GM growth 3Y14.12%
GM growth 5Y2.16%
F-Score6
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | 0.3 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 67.17% | ||
| Cap/Sales | 5.7% | ||
| Interest Coverage | 37.14 | ||
| Cash Conversion | 121.25% | ||
| Profit Quality | 227.48% | ||
| Current Ratio | 3.3 | ||
| Quick Ratio | 1.93 | ||
| Altman-Z | 3.11 |
F-Score6
WACC8.97%
ROIC/WACC0.66
Cap/Depr(3y)51.63%
Cap/Depr(5y)66.68%
Cap/Sales(3y)4.57%
Cap/Sales(5y)4.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.09%
EPS 3YN/A
EPS 5Y-13.6%
EPS Q2Q%75%
EPS Next Y16.71%
EPS Next 2Y24.22%
EPS Next 3Y28.03%
EPS Next 5YN/A
Revenue 1Y (TTM)11.83%
Revenue growth 3Y15.82%
Revenue growth 5Y4.82%
Sales Q2Q%16.65%
Revenue Next Year12.1%
Revenue Next 2Y10.7%
Revenue Next 3Y9%
Revenue Next 5YN/A
EBIT growth 1Y72.33%
EBIT growth 3YN/A
EBIT growth 5Y-2.54%
EBIT Next Year111.37%
EBIT Next 3Y35.88%
EBIT Next 5YN/A
FCF growth 1Y130.07%
FCF growth 3YN/A
FCF growth 5Y7.84%
OCF growth 1Y127.24%
OCF growth 3YN/A
OCF growth 5Y11.54%